People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics, Inc | — | Biotechnology | Growth/Late | $1.2B | $8.4B | 2014 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2015 |
| Allena Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $80.5M | $75.0M | 2014 |
| Artax Biopharma, Inc. | — | Biotechnology | Series B | $48.0M | $75.7M | 2019 |
| Enalare Therapeutics Inc. | — | Pharmaceuticals | Series A | $23.5M | $150.7M | 2020 |
Gino Santini at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gino Santini on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gino W. Santini | 2 | 3 |
| Michael Williams | 1 | 27 |
| Bryan Roberts | 1 | 18 |
| David Hirsch | 1 | 16 |
| James Topper | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Ed Mathers | 1 | 11 |
| Peter B. Finn | 1 | 11 |
| John Freund | 1 | 7 |
| Robert Tepper | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| Stephen Kraus | 1 | 7 |
| PATRICK CONWAY | 1 | 6 |
| Axel Bolte | 1 | 6 |
| Casper Breum | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Michael Heffernan | 1 | 5 |
| Kurt Graves | 1 | 5 |
| Eran Nadav | 1 | 4 |
| Paul Brannelly | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.